Applications of proteomics to osteoarthritis, a musculoskeletal disease characterized by aging. by Mobasheri, A
PERSPECTIVE ARTICLE
published: 23 December 2011
doi: 10.3389/fphys.2011.00108
Applications of proteomics to osteoarthritis, a
musculoskeletal disease characterized by aging
Ali Mobasheri*
Musculoskeletal Research Group, Division of Veterinary Medicine, School of Veterinary Medicine and Science, University of Nottingham, Nottingham, UK
Edited by:
Alexandrina Ferreira Mendes,
University of Coimbra, Portugal
Reviewed by:
Alexandrina Ferreira Mendes,
University of Coimbra, Portugal
*Correspondence:
Ali Mobasheri , School of Veterinary
Medicine and Science, University of
Nottingham, Sutton Bonington
Campus, Sutton Bonington,
Nottingham, Leicestershire LE12
5RD, UK.
e-mail: ali.mobasheri@nottingham.
ac.uk
The incidence of age-related musculoskeletal impairment is steadily rising throughout the
world. Musculoskeletal conditions are closely linked with aging and inﬂammation. They
are leading causes of morbidity and disability in man and beast. Aging is a major con-
tributor to musculoskeletal degeneration and the development of osteoarthritis (OA). OA
is a degenerative disease that involves structural changes to joint tissues including syn-
ovial inﬂammation, catabolic destruction of articular cartilage and alterations in subchondral
bone. Cartilage degradation and structural changes in subchondral bone result in the pro-
duction of fragments of extracellular matrixmolecules. Some of these biochemical markers
or “biomarkers” can be detected in blood, serum, synovial ﬂuid, and urine and may be use-
ful markers of disease progression.The ability to detect biomarkers of cartilage degradation
in body ﬂuids may enable clinicians to diagnose sub-clinical OA as well as determining the
course of disease progression. New biomarkers that indicate early responses of the joint
cartilage to degeneration will be useful in detecting early, pre-radiographic changes. Sys-
tems biology is increasingly applied in basic cartilage biology and OA research. Proteomic
techniques have the potential to improve our understanding of OA physiopathology and its
underlying mechanisms. Proteomics can also facilitate the discovery of disease-speciﬁc
biomarkers and help identify new therapeutic targets. Proteomic studies of cartilage and
other joint tissues may be particularly relevant in diagnostic orthopedics and therapeutic
research. This perspective article discusses the relevance and potential of proteomics for
studying age-related musculoskeletal diseases such as OA and reviews the contributions
of key investigators in the ﬁeld.
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THE GLOBAL CHALLENGE OF MUSCULOSKELETAL DISEASES
CHARACTERIZED AND EXACERBATED BY AGING
The incidence of age-related diseases is rising, seriously affecting
the health of millions of people around the world. According to
the United Nations (UN)1 and the World Health Organization
(WHO)2 musculoskeletal, rheumatic, and arthritic conditions are
leading causes of morbidity and disability throughout the world,
giving rise to enormous healthcare expenditures and loss of work
(Woolf and Pﬂeger, 2003; source: http://www.arthritis.org/)3,4.
Many types of rheumatic diseases and arthritic conditions are
essentially age-related“inﬂammatory”disorders where the inﬂam-
mation facilitates disease progression. The term “arthritis” char-
acterizes a group of conditions involving inﬂammatory damage to
synovial joints (Di Paola and Cuzzocrea, 2008). Arthritis literally
means inﬂammation (itis) of the joints (arthr). It involves pain,
redness, heat, swelling, and other harmful effects of inﬂammation
within the joint. There are over 200 different forms of arthritis.
However, the most common and important form of arthritis is
1http://www.un.org/
2http://www.who.int/en/
3http://www.who.int/healthinfo/statistics/bod_osteoarthritis.pdf
4http://whqlibdoc.who.int/bulletin/2003/Vol81-No9/bulletin_2003_81(9)_630.pdf
osteoarthritis (OA), also known as osteoarthrosis or degenerative
joint disease (DJD). OA is the most prevalent of the chronic dis-
eases affecting the elderly (Aigner et al., 2004). The majority of
the population over 65 years of age demonstrate radiographic evi-
dence of OA in at least one joint. Although OA is rare in people
under 40, it becomes much more common with age. More than
20 million Americans are estimated to have OA5. A 2005 study in
the USA estimated that OA is one of the top ﬁve causes of disabil-
ity amongst non-hospitalized adults [source: Center for Disease
Control (CDC6), USA]. In 2006 it was estimated that around 35
million to 40 million Europeans suffer from OA and nearly 25%
of people aged 60 and above suffer from OA induced disability. It
is also anticipated that by the year 2030, 20% of adults will have
developed OA in Western Europe and North America. Therefore,
OA is expected to place a heavy economic burden on healthcare
systems and community services throughout the world. The risk
factors forOA are well known and include age, overweight/obesity,
underlying metabolic or endocrine disease, genetics, and joint
trauma (Lotz and Kraus, 2010). With increasing life expectancy,
growth in the elderly population and an alarming escalation of
5http://www.niams.nih.gov/
6http://www.cdc.gov/
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chronic, inﬂammatory, and age-related conditions (such as OA),
there is increased demand for new treatments and preventative
approaches.
ARTICULAR CARTILAGE STRUCTURE AND FUNCTION
Articular cartilage is the main tissue involved in OA. It is a
mechanically unique and resilient connective tissue responsible
for load-bearing and low-friction movement in the synovial joints
of all vertebrates (Buckwalter et al., 2005). Cartilage is avascular
and as a consequence it has a very limited capacity for intrinsic
repair (Brittberg, 1999; Tew et al., 2001). It highly prone to struc-
tural degradation making it particularly difﬁcult to restore once
it is damaged or lost. The extracellular matrix (ECM) of carti-
lage gives the tissue resilience and elasticity. The ECM consists
of three classes of molecules: collagens, aggregating proteogly-
cans, and non-collagenous proteins. Type II, IX, and XI collagens
form a ﬁbrillar framework of macromolecules that give the tis-
sue form, tensile stiffness, and mechanical strength (Buckwalter
and Mankin, 1998b; Eyre, 2004). Large aggregating proteoglycans
(predominantly aggrecan) allow cartilage to swell and resist com-
pressive forces (Hardingham and Fosang, 1992; Kuettner, 1992).
Small proteoglycans including decorin, biglycan, and ﬁbromod-
ulin, bind to other matrix macromolecules and help to stabilize
the ECM. Other collagenous and non-collagenous macromole-
cules present within the ECM perform a variety of structural and
informational roles, facilitate cell–cell and cell-matrix interactions,
and bind growth factors (Hardingham and Fosang, 1992; Feng
et al., 2006). The chondrocyte is the only cell type present in artic-
ular cartilage (Archer and Francis-West, 2003). During embryonic
development chondrocytes synthesize a cartilaginous template for
endochondral ossiﬁcation and skeletal development and in post-
natal life they maintain the ECM by regulating the turnover of
matrix components in response to biomechanical, biochemical,
and endocrine signals (Goldring and Marcu, 2009). Chondro-
cytes actively synthesize new ECM components as well as the
proteolytic enzymes such as matrix metalloproteinases (MMPs),
a disintegrin, and metalloproteinase (ADAMs) and a disintegrin
and metalloproteinase with thrombospondin motifs (ADAMTSs)
are responsible for tissue remodeling during development. These
enzymes are also involved in the catabolic breakdown of cartilage
in OA (Aigner et al., 2006).
CARTILAGE DEGRADATION IN OSTEOARTHRITIS
Osteoarthritis is a degenerative disease that involves joint inﬂam-
mation, bone remodeling, and catabolic destruction of the artic-
ular cartilage component (Goldring and Goldring, 2007; Samuels
et al., 2008). InOA there is an imbalance between the synthesis and
degradation of ECM macromolecules (Felson, 2004). This can be
due to increased enzymatic activity of MMPs (Okada et al., 1992),
and pro-inﬂammatory mediators such as cytokines (Goldring and
Goldring, 2004), prostaglandins, and nitric oxide (Goldring and
Berenbaum, 2004), coupled with the reduced anabolic capacity
of chondrocytes (Aigner et al., 1997) and the tissue’s inherently
poor reparative capacity due to its avascular nature (Archer and
Francis-West, 2003). Consequently OA is characterized by the loss
of structural constituents from the ECM. The degradation and
release of proteins and glycoproteins from cartilage in OA can vary
according to the stage of the disease process. For example, elevated
serum cartilage oligomeric matrix protein (COMP) is correlated
with the presence of OA and disease severity (Clark et al., 1999).
AGING AND OSTEOARTHRITIS
Aging is a major contributor to musculoskeletal degeneration and
the development of OA (Hamerman, 1998; Lotz and Carames,
2011). Age-related changes in articular cartilage contribute to the
development andprogressionofOA.Although thedegenerationof
articular cartilage is not simply the result of aging and mechanical
wear, aging nevertheless modiﬁes the articular joint including car-
tilage, subchondral bone,muscle, soft tissues, synovial membrane,
and synovial ﬂuid (Buckwalter and Mankin, 1998a; Hamerman,
1998). Although older age is the greatest risk factor for OA, OA
is not an inevitable consequence of growing old (Shane Anderson
and Loeser, 2010). Themechanisms for the link between aging and
OA are incompletely understood. Cell stress and oxidative dam-
age contribute to chronic inﬂammation that promotes age-related
diseases. In OA this results in senescence-associated secretory phe-
notype, which has many of the characteristics of an osteoarthritic
chondrocyte in terms of the cytokines, chemokines, and proteases
produced (Loeser, 2011).
BIOMARKERS OF OSTEOARTHRITIS
A major focus of clinical research in recent years has been the
identiﬁcation of new disease markers that can facilitate early diag-
nosis and optimize individualized treatments. Such markers can
also facilitate the drug discovery process by reducing the high lev-
els of attrition in clinical trials. A biomarker is classically deﬁned
as a biochemical entity that is used to measure the progress of
a disease or the effects of treatment on clinical outcome. Bio-
chemical markers can be measured in blood, serum, and urine
or a variety of other body ﬂuids and tissues. The National Can-
cer Institute (NCI)7 deﬁnes a biomarker as “a biological molecule
found in blood, other body ﬂuids, or tissues that is a sign of a
normal or abnormal process, or of a condition or disease,” and the
terms“molecularmarkers”or“signaturemolecules”have also been
used to describe such markers. The term biomarker is all encom-
passing and can include proteins, protein fragments, metabolites,
carbohydrates, nucleic acids (RNA and DNA), cellular features,
and images.
Osteoarthritis is unambiguously diagnosed when it is
“detected” by the best available test. Thus far the best test for
this purpose has been radiography, the so-called “gold-standard.”
This process also requires clinical signs in the patient, which often
occur well into the progression of the disease. However, there is
often early, pre-clinical evidence of disease provided by various
biomarkers, which if detected, may facilitate earlier diagnosis and
treatment. Such an approach is particularly pertinent in the case
of OA, a disease often characterized by a prolonged pre-clinical
“molecular” phase, a “pre-radiographic” phase, and a “recalcitrant
radiographic” phase by which time there are structural changes
to joints along with pain and loss of function. Biomarkers have
the potential to provide an early warning of joint degeneration
7http://www.cancer.gov/
Frontiers in Physiology | Striated Muscle Physiology December 2011 | Volume 2 | Article 108 | 2
Mobasheri Proteomics and osteoarthritis
which could prompt earlier, more targeted treatment to prevent
the tissue destruction that results in the characteristic chronic dis-
ability associated with OA. In this context, biomarkers could make
a signiﬁcant contribution to the early diagnosis of OA, as well
as informing key aspects of disease prognosis, monitoring, and
therapy.
The National Institute of Arthritis and Musculoskeletal and
Skin Diseases (NIAMS) established the Osteoarthritis Biomarkers
Network8 to develop and validate standardized, sensitive bio-
marker assays in blood and urine to facilitate the diagnosis of the
pre-radiologic stage of OA in humans and in animal models. Such
markers can help us understand the biological processes involved
in disease progression and allow us to monitor the effects of sur-
gical or pharmacological treatment, thus accelerating the pace of
drug discovery. Such biomarkers could also potentially be used
to identify patients at increased risk of developing OA. Existing
biomarkers of OA have major limitations: they do not “ﬂag” the
pre-radiographic phase of the disease; they are not speciﬁc for the
various stages of OA, and in some cases, may not even be speciﬁc
for OA.
Considering these challenges, the Osteoarthritis Research Soci-
ety International (OARSI)9 and the US Food and Drug Adminis-
tration (FDA)10 have recently established a new OA biomarkers
working group, which has proposed the division of potential
markers into two major groups: the so-called soluble or “wet”
biomarkers, which typically reﬂect a modulation in an endoge-
nous substance in body ﬂuids such blood, serum, plasma, urine,
or synovial ﬂuid); and the “dry” biomarkers, which usually consist
of visual analog scales, performed tasks, or images of joints (Kraus
et al., 2011).
Therefore, the ability to detect biomarkers of cartilage degra-
dation and/or inﬂammation in biological samples, such as serum,
urine, or synovial ﬂuid, may enable clinicians to diagnose sub-
clinical OA as well as determining the disease stage in both human
and companion animals. Identifying these biomarkers will also
aid drug discovery and drug safety/efﬁcacy monitoring in patients
and in animal models. Using combinations of biomarkers may
be more effective in achieving these goals, thus having a panel of
biomarkers will help researchers and the pharmaceutical industry
to monitor disease progression as well as to assess responses to
treatment in experimental models of OA (Rousseau and Delmas,
2007; Williams, 2009).
SYSTEMS BIOLOGY AND PROTEOMIC APPROACHES FOR
THE DISCOVERY OF OSTEOARTHRITIS BIOMARKERS
Systems biology is increasingly applied in orthopedics and rheu-
matology to cartilage and synovium in arthritis. These techniques
include genomics, transcriptomics, proteomics, metabolomics,
glycomics, and bioinformatics and can be applied to the study
of cartilage, synovium, synovial ﬂuid, and even blood (serum) or
urine from OA patients. Proteomics involves the application of
specialized analytical techniques that allow the evaluation of the
protein composition of tissues, cells, and culture supernatants.
8http://www.nih.gov/niams/
9http://www.oarsi.org/
10http://www.fda.gov/
Proteomics is being increasingly applied in basic cartilage biol-
ogy (Polacek et al., 2010) and OA research (Ruiz-Romero et al.,
2010). Characterization of cell lysates from isolated chondrocytes
has yielded valuable information regarding the intracellular pro-
teins of the chondrocyte proteome, and paved the way for future
studies on cartilage pathologies such as OA (Ruiz-Romero et al.,
2005; Ruiz-Romero and Blanco, 2010). Studies of soluble proteins
in cartilage tissue from OA patients has increased the knowledge
of the proteins contained within the ECM of diseased versus nor-
mal tissue (Wu et al., 2007). A number of papers have reported on
proteins secreted from the cartilage ECM in response to patholog-
ical insults such as interleukin (IL)-1α and all-trans-retinoic acid
(Wilson et al., 2008a,b; Ruiz-Romero and Blanco, 2010), IL-1β and
TNF-α (Cillero-Pastor et al., 2010) and mechanical compression
(Stevens et al., 2008; Zhang and Wang, 2009; Li et al., 2010). Iden-
tifying proteins released from cartilage has the potential to give an
indication of disease biomarkers likely to be present in the synovial
ﬂuid or blood of patients in the early stages of OA.
RELEVANCE OF BIOMARKERS AND PROTEOMIC
TECHNIQUES TO “PHYSIOLOGY AND PATHOPHYSIOLOGY OF
MUSCULOSKELETAL AGING”
Understanding healthy aging is a key research priority, along with
a better understanding of the pathophysiology of aging that occurs
in a number of age-related diseases, such as arthritis. By gaining
a better understanding of healthy musculoskeletal aging we can
provide better care and new therapies for common musculoskele-
tal problems.“Physiology and Pathophysiology of Musculoskeletal
Aging” is a Research Topic that is intended to bring together basic
researchers and clinicians working in the broad area of muscu-
loskeletal aging. The topic includesmechanismsof healthy aging in
tissues of themusculoskeletal system (i.e., skeletalmuscle, articular
cartilage, subchondral bone, tendon, and ligament).
The discovery and validation for biomarkers of OA has accel-
erated signiﬁcantly as our understanding of joint tissue molecules
and their complex interactions have increased (Kraus, 2005). One
of the main drivers in this context has been the urgent need
for improved OA “outcome measures” in clinical trials (Kraus,
2005; Hunter et al., 2010). In particular there is a pressing need
for new biomarkers that indicate early responses of the joint
cartilage to degeneration that will be useful in detecting early,
pre-radiographic changes. Novel markers that characterize the
status and prognosis of OA, and that can be used to monitor
response to therapy are also required (Mobasheri and Henrotin,
2010). Current “omics-based” research aims to develop an “ana-
lytical toolbox” which is hoped will contribute to the clinical
development process (Bay-Jensen et al., 2010; Qvist et al., 2010).
Combinations of existing biomarkers may improve their prognos-
tic accuracy andhelp identify at-risk patients (Williams,2009). The
challenge is to use proteomics and other “omics-based” technolo-
gies in order to identify sensitive and reliable pre-radiographic
biomarkers that can be accurately and reproducibly measured in
body ﬂuids. Biomarkers that “ﬂag” early stage OA will be particu-
larly useful in curbing disease progression by identifying patients
that would beneﬁt from early therapeutic intervention.
In this Research Topic Gharbi and co-workers (Gharbi et
al., 2011) review the applications of proteomic techniques for
studying OA. Their aim is to improve our understanding of the
www.frontiersin.org December 2011 | Volume 2 | Article 108 | 3
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physiopathology of the disease its underlying mechanisms and to
discover disease-speciﬁc biomarkers and identify new therapeutic
targets. This timely and focused review summarizes the currently
available data regarding proteomic techniques and their applica-
tions toOA research. The authors discuss technical limitations and
solutions to real and practical problems including sample prepara-
tion. Although proteomics has many potential applications in this
area, there are technical challenges that still remain. This elegant
and original article highlights the major issues facing researchers
in this area.
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